Roche reiterated its full-year guidance and announced it is prepared to launch its giredestrant breast-cancer pill later this year. The Swiss pharmaceutical giant reported higher sales driven by growth across its Pharma and Diagnostics units. The company maintained its outlook despite ongoing developments in its oncology pipeline.
Roche's diagnostics division continued to perform strongly, contributing to the overall positive financial performance. The upcoming launch of giredestrant marks a significant expansion in the company's breast cancer treatment offerings.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing